How to buy Galmed Pharmaceuticals stock

Galmed Pharmaceuticals Ltd is a biotechnology business based in the US. Galmed Pharmaceuticals shares (GLMD) are listed on the NASDAQ and all prices are listed in US Dollars. Galmed Pharmaceuticals employs 18 staff and has a market cap (total outstanding shares value) of 0.00.

Galmed Pharmaceuticals share price

Use our graph to track the performance of GLMD stocks over time.

Galmed Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-04-29.

52-week range	$2.96 - $6.20
50-day moving average	$3.39
200-day moving average	$3.61
Wall St. target price	$16.40
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.59

Buy Galmed Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Galmed Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Galmed Pharmaceuticals Ltd by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Galmed Pharmaceuticals financials

Gross profit TTM	$0
Return on assets TTM	-29.16%
Return on equity TTM	-50.47%
Profit margin	0%
Book value	$2.07
Market capitalisation	$84.5 million

TTM: trailing 12 months

Shorting Galmed Pharmaceuticals shares

There are currently 331,743 Galmed Pharmaceuticals shares held short by investors – that's known as Galmed Pharmaceuticals's "short interest". This figure is 15.1% up from 288,274 last month.

There are a few different ways that this level of interest in shorting Galmed Pharmaceuticals shares can be evaluated.

Galmed Pharmaceuticals's "short interest ratio" (SIR)

Galmed Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Galmed Pharmaceuticals shares currently shorted divided by the average quantity of Galmed Pharmaceuticals shares traded daily (recently around 265394.4). Galmed Pharmaceuticals's SIR currently stands at 1.25. In other words for every 100,000 Galmed Pharmaceuticals shares traded daily on the market, roughly 1250 shares are currently held short.

However Galmed Pharmaceuticals's short interest can also be evaluated against the total number of Galmed Pharmaceuticals shares, or, against the total number of tradable Galmed Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Galmed Pharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Galmed Pharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.0154% of the tradable shares (for every 100,000 tradable Galmed Pharmaceuticals shares, roughly 15 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Galmed Pharmaceuticals.

Find out more about how you can short Galmed Pharmaceuticals stock.

Galmed Pharmaceuticals share dividends

We're not expecting Galmed Pharmaceuticals to pay a dividend over the next 12 months.

Galmed Pharmaceuticals share price volatility

Over the last 12 months, Galmed Pharmaceuticals's shares have ranged in value from as little as $2.96 up to $6.2. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Galmed Pharmaceuticals's is 2.1804. This would suggest that Galmed Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Galmed Pharmaceuticals overview

Galmed Pharmaceuticals Ltd. , a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co.

Frequently asked questions

• What percentage of Galmed Pharmaceuticals is owned by insiders or institutions?

  Currently 14.138% of Galmed Pharmaceuticals shares are held by insiders and 26.23% by institutions.

• How many people work for Galmed Pharmaceuticals?

  Latest data suggests 18 work at Galmed Pharmaceuticals.

• When does the fiscal year end for Galmed Pharmaceuticals?

  Galmed Pharmaceuticals's fiscal year ends in December.

• Where is Galmed Pharmaceuticals based?

  Galmed Pharmaceuticals's address is: 16 Tiomkin Street, Tel Aviv, Israel, 6578317

• What is Galmed Pharmaceuticals's ISIN number?

  Galmed Pharmaceuticals's international securities identification number is: IL0011313900

• What is Galmed Pharmaceuticals's CUSIP number?

  Galmed Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: M47238106